

Appendix 4D

Half-yearly report
Botanix Pharmaceuticals Limited
ABN 70 009 109 755

1. Company details

Name of entity:	Botanix Pharmaceuticals Limited
ABN:	70 009 109 755
Reporting period:	For the half-year ended 31 December 2024
Previous period:	For the half-year ended 31 December 2023

2. Results for announcement to the market

	31 Dec 2024	31 Dec 2023	% change
Revenues from ordinary activities	345,673	377,930	(8.54)%
Profit (Loss) from continuing operations after tax attributable to the owners of Botanix Pharmaceuticals Limited	(30,888,119)	(5,467,164)	(464.98%)
Profit (Loss) for the half-year attributable to the owners of Botanix Pharmaceuticals Limited	(30,888,119)	(5,467,164)	(464.98%)

3. Net tangible assets per security

	31 Dec 2024 Cents	30 Jun 2024 Cents
Net tangible asset per ordinary security	<u>3.40</u>	<u>4.38</u>

4. Dividends

No dividends were paid during the current or previous financial years and no dividends have been declared subsequent to the financial year end and up to the date of this report.

5. Dividend reinvestment plans

There are no dividend or distribution reinvestment plans in operation.

6. Foreign entities

Not applicable.

7. Gain or loss of control over entities

There were no entities over which control was gained or lost during the half-year ended 31 December 2023.

8. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

9. Attachments

Details of attachments (if any):

The Interim Report of Botanix Pharmaceuticals Limited for the half-year ended 31 December 2024 is attached.

10. Signed



Vince Ippolito
Executive Chairman

Date: 25 February 2025



ACN 009 109 755

HALF YEAR REPORT

for the half year ended 31 December 2024

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CONTENTS

CORPORATE INFORMATION	3
DIRECTORS' REPORT	4
AUDITOR'S INDEPENDENCE DECLARATION	9
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	10
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	12
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	13
CONSOLIDATED STATEMENT OF CASH FLOWS	14
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	15
DIRECTORS' DECLARATION	30
INDEPENDENT AUDITOR'S REVIEW REPORT	31

This financial report covers Botanix Pharmaceuticals Limited ("Botanix" or the "Company") and its subsidiaries ("Group"). The financial report is presented in Australian dollars.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CORPORATE INFORMATION

Directors

Mr Vince Ippolito
Executive Chairman

Mr Matthew Callahan
Executive Director

Dr William Bosch
Non-Executive Director

Dr Stewart Washer
Non-Executive Director

Mr Danny Sharp
Non-Executive Director

Company Secretary

Ms Susan Park

Home Securities Exchange:

Australian Securities Exchange Limited
Level 40, Central Park
152 – 158 St George's Terrace
PERTH WA 6000

ASX Code: BOT

Share Registry

Automic Registry Services
Level 2, 267 St Georges Terrace
PERTH WA 6007
Telephone: (08) 9324 2099

Registered Office

Suite 3
41 – 47 Colin Street
West Perth Western Australia 6005
Australia
+61 8 6285 0083

Email: info@botanixpharma.com

Website: www.botanixpharma.com

Solicitors

Gilbert + Tobin
Level 16, Brookfield Place
Tower 2
123 St Georges Terrace
PERTH WA 6000

Auditor

BDO Audit Pty Ltd
Level 9, Mia Yellagonga Tower 2
5 Spring Street
Perth WA 6000

Bankers

NAB
100 St Georges Terrace
Perth WA 6000

DIRECTORS' REPORT

The Directors of Botanix Pharmaceuticals Limited (Botanix, the Company or Group) present the following report for the half-year ended 31 December 2024:

DIRECTORS

The Directors in office at any time during the half year and until the date of this report, unless otherwise stated, are set out below:

Mr Vince Ippolito

Executive Chairman

Mr Matthew Callahan

Executive Director

Dr William Bosch

Non-Executive Director

Dr Stewart Washer

Non-Executive Director

Mr Danny Sharp

Non-Executive Director

PRINCIPAL ACTIVITIES

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical dermatology company based in Philadelphia and Phoenix (US) which markets *Sofdra*® (sofpironium) topical gel, 12.45%. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis, the third largest dermatology condition (after acne and atopic dermatitis), which impacts approximately 10 million patients in the US.¹ The disproportionate sweat production that characterises hyperhidrosis, results in a disabling medical condition with profound effects on the patient's quality of life.²

¹ Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research.

² Hamm H, Naumann MK, Kowalski JW, Kutt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353. doi: 10.1159/000092285

RESULTS

The Group incurred a net loss after income tax for the six months ended 31 December 2024 of \$30,888,119 (2023: loss of \$5,467,164) as a result of the ramp up to selling *Sofdra*. During the half year, Botanix incurred expenses of \$8,862,001 (2023: \$nil) for product sales and marketing initiatives, \$6,077,332 of employee costs (2023: \$1,399,513) including salaries of its sales force employees, and ended the period with capitalised costs of \$17,078,096 in product inventory (30 June 2024: \$1,209,374) to meet anticipated demand. Included in the loss is \$10,593,334 of non-cash share based payments expense (31 December 2023: \$1,493,222).

Botanix earned \$1,182,311 (2023: \$41,559) of interest income on its significant cash holdings throughout the half-year period and continued to earn royalties from sales of sofipironium bromide in Japan by its partner Kaken. During the half-year period, the Group recognised \$345,673 in net royalty revenues (2023: \$377,930 in net royalty revenues).

REVIEW OF OPERATIONS AND RESULTS

OPERATIONS

Overview

The six-month reporting period ending on 31 December 2024 (H1 FY24), reflected a number of important milestones for Botanix, with the approval of *Sofdra* on June 18, 2024, followed by the first prescriptions for *Sofdra* being issued as part of the Patient Experience Program in December, and subsequent first refills being provided to patients. All of the patients in the patient experience program who received prescriptions successfully utilised the telehealth platform and received both their initial prescriptions and refills directly to their residences. Successful clearance of relevant payer requirements and frictionless buy down of the patients' monthly co-pay (or gap payment), also meant that 100% of patients received their refills in January, proving up the telehealth and closed fulfilment system in advance of full commercial launch.

The period also provided confirmation that prescriptions representing all the targeted payers were handled in accordance with the negotiated terms, meaning that no additional requirements were imposed for insurance approval, and where proof of diagnosis (or having tried *Drysol*® or its equivalent) was required – this information was seamlessly provided to the payer and cleared relevant approvals.

Sales infrastructure and territory managers in the field

During the period, Botanix's broader preparations for the full commercial launch of *Sofdra* were finalized, with the engagement of all regional managers, territory managers and marketing support positions as well as development of sales and marketing materials for field launch. Botanix has now engaged 27 territory managers (sales professionals), including some of the most credentialed individuals in the dermatology industry, with 79 'President Club' wins (awarded to the top 10% of sales professionals annually) between them. Extensive online and in person

training has now been completed, utilizing the newly prepared and approved sales support materials, and this training has recently been certified at the Company's first national sales meeting just completed on 30 January at our offices in Phoenix, Arizona.

Botanix's highly motivated sales representatives are now calling on dermatologists, to commence educating physicians and driving prescriptions, as part of the full commercial launch of *Sofdra*. They are equipped with interactive tablet-based explainers and supported by a new full product website and telehealth and patient facing pharmacy portal.

With less than 10 employees and contractors at the time of *Sofdra* approval in June 2024, the Botanix team has now grown to 25 (not including the territory managers who formally joined us in early January). Drawing talent from leading dermatology and specialty pharmaceutical companies in the USA with an average of over 20 years' experience, the Botanix team is now fully staffed and ready to accelerate prescriptions and revenue.

Knowledge gained from the *Sofdra* Patient Experience Program, created in collaboration with the International Hyperhidrosis Society, has provided valuable feedback from early patient access to *Sofdra*. The program has now ended and these (now) commercial users of the product, have provided actionable feedback regarding the telemedicine and fulfillment experience that Botanix has used to refine its processes ahead of the broader launch to significantly larger volumes of patients in Q1 CY2025.

Commercial infrastructure and payers

The Botanix team has also extended its manufacturing activities to ensure that sufficient inventories of Sofpironium Bromide drug, *Sofdra* bottles, applicators and other materials were made available to cover anticipated demand and able to be flexed to accommodate any accelerations in sales forecasts. The Company has now successfully completed multiple manufacturing campaigns, and has bottled and packaged finished product at our partner manufacturing facility at CPL, as well as successfully utilised the logistics infrastructure responsible for transport, warehousing and supply to our pharmacy network, SendRx. Data infrastructure, pharmacy and telemedicine systems have also been integrated and tested, and first refills have been provided to the Patient Experience Program participants in advance of full commercial launch this quarter.

Botanix has also finalised contractual terms with all the key US commercial payers, which reflect the target financial and patient access restrictions previously discussed with them and as communicated to shareholders. The restrictions require a simple confirmation of diagnosis for primary axillary hyperhidrosis as per the label, and that the patient has tried aluminum chloride as a prior therapy, with some only requiring simply the confirmation of diagnosis. These payers represent 167 million commercial lives who will be accessible for the full launch of *Sofdra* this half.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

Botanix has also now completed all legal requirements for US government payer programs, with the consequence that from March 2025, *Sofdra* will be also government reimbursed for approximately 80 million additional government insured lives.

Following first prescriptions from the Patient Experience Program in December (which have provided first modest revenues from *Sofdra*), Botanix expects that Q1 CY2025 will represent the first commercial revenue quarter, with 100% of refills from those first prescriptions already being successfully filled.

With the sales team in the field since the beginning of February, the launch is progressing on plan and the digital program is on track to launch in March, with full social and paid media outreach amongst other workstreams. We expect that Q2 CY2025 will reflect a ramp on the Q1 revenue run rate, with the full deployment of both direct and digital sales channels.

As the Company moves into full commercialisation for *Sofdra*, we will leverage our data infrastructure to also report leading indicators for prescription performance and refills, that ultimately drive revenue from quarter to quarter, such as:

- refill rate performance;
- patient satisfaction metrics, including ship times and efficiency of the telehealth/fulfilment platform;
- performance of digital media spend, reach and conversion; and
- physician and patient feedback and cycle times.

Following the success of the Company's commercial update briefings in 2024, Botanix also plans to speak to these indicators in new quarterly investor briefings this year, following lodgement of each quarterly report.

Corporate

During the half-year period, the following options were exercised and corresponding ordinary shares issued:

Exercise price	Exercise technique	Number of options exercised	Cash received by the Company
\$0.089	Cashless	3,422,643 ⁽¹⁾	N/A
\$0.132	Cash	2,000,000	\$264,000
\$0.099	Cash	2,000,000	\$198,000

(1) 4,500,000 options were exercised using the cashless facility resulting in 3,422,643 of ordinary shares issued.

BOTANIX PHARMACEUTICALS LIMITED**ACN: 009 109 755**

On 12 July 2024, the Company issued the following employee options and performance rights to employees of which were previously granted by 30 June 2024 but not yet formally issued:

Instrument	Exercise price	Expiry date	Number issued
Performance Rights	\$nil	12 April 2029	15,000,000
Performance Rights	\$nil	30 September 2028	8,000,000
Options	\$0.364	12 July 2027	2,000,000
Options	\$0.28	12 July 2027	4,000,000
Options	\$0.24	12 July 2028	10,000,000

As approved by shareholders at the Company's Annual General Meeting, held on 4 November 2024, performance rights were issued to *key management personnel* of the Board of Directors as follows:

Exercise price	Expiry date	Number granted
\$nil	2 December 2029	36,000,000


Details to the performance hurdles and valuation of performance rights issued during the period are as disclosed further in this half-year report. Refer to note 6.

EVENTS SINCE THE END OF THE FINANCIAL PERIOD

On 9 January 2025, the Company issued 12,000,000 performance rights and 31,250,000 options to employees and staff. These instruments were deemed to be granted, for accounting purposes, prior to 31 December 2024 period and therefore accounted for within the 31 December 2024 period or, in the case of 3,000,000 of the options, during the 30 June 2024 period. Refer to Note 6 for details to the 40,250,000 of securities granted during the 31 December 2024 period.

The Auditor's Independence Declaration is set out on page 9 and forms part of the Directors' Report for the half year ended 31 December 2024.

Signed in accordance with a resolution of the Directors.



Vince Ippolito
Executive Chairman
25 February 2025

DECLARATION OF INDEPENDENCE BY DEAN JUST TO THE DIRECTORS OF BOTANIX
PHARMACEUTICALS LIMITED

As lead auditor for the review of Botanix Pharmaceuticals Limited for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Botanix Pharmaceuticals Limited and the entities it controlled during the period.



Dean Just
Director

BDO Audit Pty Ltd
Perth
25 February 2025

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the half-year ended 31 December 2024

	Note	Consolidated 31 December 2024 \$	Consolidated 31 December 2023 \$
Revenue from continuing operations			
Sales revenue		345,673	377,930
Total revenue from continuing operations		345,673	377,930
Other income			
Interest income		1,182,311	41,559
Research and Development incentive scheme		31,924	-
Total other income		1,214,235	41,559
Expenses			
Product sales and marketing		(8,862,001)	-
Materials and related expenses		(897,719)	-
Employee benefits and related expenses		(6,077,332)	(1,399,513)
Financing costs		(34,076)	(6,627)
Communications, branding and marketing		(172,070)	(118,658)
Finance, general and administrative		(868,075)	(327,442)
Legal fees, insurances and regulatory costs		(2,306,715)	(813,085)
Foreign exchange (losses) gains		(64,870)	24,215
Research and Development expensed		(138,077)	(978,208)
Corporate consulting		(1,142,813)	(765,681)
Share based payments	6	(10,593,334)	(1,493,222)
Provision for obsolete inventories		(172,841)	-
Depreciation and amortisation	3	(1,118,104)	(8,431)
Total expenses		(32,448,027)	(5,886,653)
Loss before income tax expense		(30,888,119)	(5,467,164)
Income tax benefit		-	-
Loss after income tax for the half year		(30,888,119)	(5,467,164)

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(CONTINUED)**

For the half-year ended 31 December 2024

	Note	Consolidated 31 December 2024 \$	Consolidated 31 December 2023 \$
Other Comprehensive gain/(loss) for the half year:			
Items that may be reclassified subsequently to profit or			
Foreign exchange translation difference		3,588,238	(390,198)
Other Comprehensive gain/(loss) for the period, net of		3,588,238	(390,198)
Total Comprehensive Loss for the half year attributed to members of Botanix Pharmaceuticals Limited		(27,299,881)	(5,857,362)
Basic and diluted Loss per share for the half year attributable to members of Botanix Pharmaceuticals Limited (cents):			
Basic loss per share (cents)		(1.70)	(0.38)
Diluted loss per share (cents)		(1.70)	(0.38)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2024

	Note	Consolidated 31 December 2024 \$	Consolidated 30 June 2024 \$
ASSETS			
Current Assets			
Cash and cash equivalents		48,436,870	79,308,130
Inventory	2	17,078,096	1,209,374
Trade and other receivables		799,543	817,038
Research and development incentive scheme		-	1,467,667
Prepayments		1,476,179	99,097
Total Current Assets		67,790,688	82,901,306
Non-Current Assets			
Plant and Equipment		152,402	71,777
Intangible assets	3	30,731,402	29,491,543
Right-of-use assets		773,275	-
Total Non-Current Assets		31,657,079	29,563,320
Total Assets		99,447,767	112,464,626
LIABILITIES			
Current Liabilities			
Trade and other payables	4	5,825,483	3,624,623
Provisions		267,932	107,454
Lease liabilities		281,942	-
Total Current Liabilities		6,375,357	3,732,077
Non-Current Liabilities			
Lease liabilities		584,408	-
Total Non-Current Liabilities		584,408	-
Total Liabilities		6,959,765	3,732,077
Net Assets		92,488,002	108,732,549
EQUITY			
Contributed equity	5	188,840,664	188,320,331
Share based payment reserve	7	21,237,141	10,702,140
Foreign currency translation reserve	7	4,089,957	501,719
Accumulated losses		(121,679,760)	(90,791,641)
Total Equity		92,488,002	108,732,549

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the half-year ended 31 December 2024

		Contributed Equity	Accumulated Losses	Share Based Payment Reserve	Foreign Currency Translation Reserve	Total
Note		\$	\$	\$	\$	\$
	Balance at 1 July 2024	188,320,331	(90,791,641)	10,702,140	501,719	108,732,549
	Total comprehensive loss for the period					
	Loss for the half year	-	(30,888,119)	-	-	(30,888,119)
	Total other comprehensive income	-	-	-	3,588,238	3,588,238
	Total comprehensive loss for the period	-	(30,888,119)	-	3,588,238	(27,299,881)
	Transactions with owners in their capacity as					
	Proceeds from issued capital	5	462,000	-	-	462,000
	Transaction costs from issued capital	5	-	-	-	-
	Share based payments	6	58,333	10,535,001	-	10,593,334
	Balance at 31 December 2024	188,840,664	(121,679,760)	21,237,141	4,089,957	92,488,002
	Balance at 1 July 2023	93,489,658	(76,921,932)	6,041,423	341,878	22,951,027
	Total comprehensive loss for the period					
	Loss for the half year	-	(5,467,164)	-	-	(5,467,164)
	Total other comprehensive loss	-	-	-	(390,198)	(390,198)
	Total comprehensive loss for the period	-	(5,467,164)	-	(390,198)	(5,857,362)
	Transactions with owners in their capacity as					
	Proceeds from issued capital	5	28,335,624	-	-	28,335,624
	Transaction costs from issued capital		(1,879,622)	346,981	-	(1,532,641)
	Share based payments	6	-	1,493,220	-	1,493,220
	Balance at 31 December 2023	119,945,660	(82,389,096)	7,881,624	(48,320)	45,389,868

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

CONSOLIDATED STATEMENT OF CASH FLOWS

For the half-year ended 31 December 2024

	Consolidated 31 December 2024 \$	Consolidated 31 December 2023 \$
CASHFLOWS FROM OPERATING ACTIVITIES		
Receipt from customers	847,331	811,929
Interest received	1,182,311	41,559
Research and Development	(138,077)	(1,405,636)
Payments to suppliers & employees	(33,935,689)	(3,208,094)
Finance costs	(17,013)	-
R&D tax concession received	1,499,591	-
Net cash used in operating activities	(30,561,546)	(3,760,242)
CASHFLOWS FROM INVESTING ACTIVITIES		
Payment for property, plant and equipment	(90,526)	(36,172)
Payment for intangible assets	(763,457)	(14,739,586)
Net cash used in financing activities	(853,983)	(14,775,758)
CASHFLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	-	26,000,000
Transaction costs paid from the issue of shares	-	(1,578,412)
Exercise of options	462,000	2,335,624
Repayment of principle portion of lease liability	(61,595)	-
Net cash provided by financing activities	400,405	26,757,212
Net increase/(decrease) in cash held	(31,015,124)	8,221,212
Cash and cash equivalents at beginning of period	79,308,130	10,250,395
Foreign exchange adjustment	143,864	(158,246)
Cash and cash equivalents at end of period	48,436,870	18,313,361

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 1: MATERIAL ACCOUNTING POLICIES

The half-year financial report is a general-purpose financial report prepared in accordance with AASB 134 'Interim Financial Reporting' and the Corporations Act 2001.

The half-year financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the consolidated entity. The half-year financial report should be read in conjunction with the annual financial report of Botanix Pharmaceuticals Limited as at 30 June 2024 which was prepared in accordance with the requirements of the Corporations Act 2001 and applicable Australian Accounting Standards. It is also recommended that the half-year financial report be considered together with any public announcements made by the company during the period 1 July 2024 to the date of this report in accordance with the continuous disclosure obligations of the ASX listing rules.

Basis of Accounting

The half-year financial report has been prepared on the basis of historical cost, except where stated. For the purpose of preparing the half-year financial report, the half-year has been treated as a discrete reporting period.

The half-year financial report has been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

The classification of comparative figures has been changed where the change improves the understandability of the financial information.

Going Concern

The financial statements for the period ended 31 December 2024 have been prepared on the basis that the Group is a going concern and therefore, contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business.

During the period, the Group recorded a net loss after tax of \$30,888,119 (31 December 2023: \$5,467,164). Included in the loss is \$10,593,334 of non-cash share-based payments expense (31 December 2023: \$1,493,222). The Group had a net working capital surplus of \$61,415,331 at 31 December 2024 (30 June 2024: \$79,169,320) and experienced net cash outflows from operating activities for the period of \$30,561,546 (31 December 2023: \$3,760,242). Included in the cash outflows was spend that resulted in an increase in inventories by \$15,869,532 as the Group prepares itself for sales during the second half of the financial year.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 1: MATERIAL ACCOUNTING POLICIES (continued)

The Group's progress in advancing its *Sofdra* product to achieve target sales volumes includes additional spend, most notably, on inventories and product sales and marketing. The extent of this expenditure and resulting sales, as captured in management's forecasts, are uncertain. These conditions indicate a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its asset and discharge its liabilities in the normal course of business. However, mitigating factors have been identified by the Directors as follows:

- the Group is confident in its ability to complete commercialisation of the product and achieve budgeted sales;
- the Group has the ability to control the timing of significant cash outflows such as major orders of raw materials inventories and marketing spends without adversely impacting the Group's ability to achieve sales targets during the 12-month period from the date of this Report;
- the Group has historically had success in raising capital on the Australian Securities Exchange ("ASX") and the Directors are confident the Group can raise capital on the ASX as and when required; and
- alternative means of financing are becoming available with the Group's launch of *Sofdra* and anticipated sales revenues. The Group is confident that this could be an avenue to finance short-term working capital requirements if needed

The existence and Directors' assessment of these mitigating circumstances have led the Directors to conclude that the Group is a going concern and that it will be able to meet its obligations as and when they fall due for at least 12-months from the date of signing this report. Accordingly, this financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts, or to the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.

Segment Reporting

Operating segments are reported in a manner that is consistent with the internal reporting provided to the Board of Directors. The Board, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the strategic steering committee.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 1: MATERIAL ACCOUNTING POLICIES (continued)**Impact of standards issued but not yet applied by the entity**

There were no new standards issued since 30 June 2024 that have been applied by the Group. The 30 June 2024 annual report disclosed that the Group anticipated no material impacts (amounts recognised and/or disclosed) arising from initial application of those standards issued but not yet applied at that date, and this remains the assessment as at 31 December 2024.

NOTE 2: INVENTORIES

	31 December 2024	30 June 2024
	\$	\$
Finished goods	928,453	-
Work-in-progress	2,395,168	-
Raw materials	15,326,976	3,048,634
Total gross inventory	18,650,597	3,048,634
Provision for obsolescence	(1,572,501)	(1,839,260)
Total inventory net of provision	17,078,096	1,209,374

During the half-year period, the Group has accumulated significant inventories in anticipation of sales volumes for the second half of financial year 2025.

NOTE 3: INTANGIBLE ASSETS

	31 December 2024	30 June 2024
	\$	\$
At cost	31,791,038	29,552,507
Accumulated amortisation	(1,059,636)	(60,964)
	30,731,402	29,491,543

	31 December 2024	30 June 2024
	\$	\$
Sofpironium Bromide Licences		
Opening balance	29,491,543	10,729,375
Additions	-	18,831,887
Effects of foreign currency translation	2,175,088	(8,755)
Amortisation expense	(935,229)	(60,964)
Closing balance	30,731,402	29,491,543

The Group completed an assessment of whether impairment indicators existed for its intangible assets and concluded no impairment indicators were present.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 4: TRADE AND OTHER PAYABLES

	31 December 2024	30 June 2024
	\$	\$
Current:		
Trade payables ⁽¹⁾	4,162,258	2,728,365
Accrued bonuses	1,057,053	456,202
Sundry payables & accrued expenses	606,172	440,056
	5,825,483	3,624,623

⁽¹⁾ Trade payables are non-interest bearing and are normally settled on 30-day terms.

NOTE 5: CONTRIBUTED EQUITY

	31 December 2024	31 December 2024	30 June 2024	30 June 2024
	Number	\$	Number	\$
Fully paid ordinary shares	1,817,627,097	188,840,664	1,810,037,788	188,320,331

Movements in fully paid shares on issue	Number	\$
Balance as at 1 July 2024	1,810,037,788	188,320,331
Exercise of options at \$0.099	2,000,000	198,000
Exercise of options at \$0.132	2,000,000	264,000
Exercise of options at \$0.089 ⁽¹⁾	3,422,643	-
Shares issued to consultants for services	166,666	58,333
Balance as at 31 December 2024	1,817,627,097	188,840,664

(1) These options were exercised under a cashless exercise technique whereby the holders of the option do not pay to the Company an amount equivalent to the exercise price multiplied by the number of options exercised. Rather, the option holder pays nil cash but receives a reduced number of shares relative to the number of options exercised based on a predetermined formula that considers the share price on the date of exercise relative to the exercise price. In this circumstance, the option holders exercised 4,500,000 options and received 3,422,643 ordinary shares.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 5: CONTRIBUTED EQUITY (CONTINUED)

Movements in fully paid shares on issue	Number	\$
Balance as at 1 July 2023	1,312,460,376	93,489,658
Placement at \$0.12	104,166,667	12,500,000
Placement at \$0.13	103,846,154	13,500,000
Placement at \$0.30	233,333,333	70,000,000
Exercise of options at \$0.09	48,664,095	4,379,769
Exercise of options at \$0.079	6,000,000	475,200
Cashless exercise of options by employee at \$0.089 ⁽¹⁾	1,567,161	79,360
Less: transaction costs ⁽²⁾	-	(6,103,656)
Balance as at 30 June 2024	1,810,037,788	188,320,331

⁽¹⁾ During the period, an employee exercised 2,666,666 of options previously awarded as a share-based payment. These options were exercised using the cashless exercise method available to employees.

⁽²⁾ As part of the placements completed during the period, the Company issued 8,000,000 options to the lead manager. The total value of these options included as transaction costs was \$346,981.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS

	Number 31 December 2024	Number 30 June 2024
Issued Options		
Unlisted Options	54,033,333	46,533,333
Movements in options on issue		
Balance as at 1 July	46,533,333	59,500,000
Add: Options issued ⁽¹⁾	16,000,000	10,450,000
Less: Options exercised ⁽²⁾	(8,500,000)	(8,666,666)
Less: forfeiture of options by employees	-	(2,083,334)
Less: Expiry/cancellation of unlisted options	-	(12,666,667)
Closing balance	54,033,333	46,533,333

31 December 2024 notes:

⁽¹⁾The Company formally issued 16,000,000 options to employees on 12 July 2024. These options were granted to employees, for accounting purposes, during the 30 June 2024 financial period.

⁽²⁾On 4 September 2024, option holders exercised 2,000,000 options at \$0.099 and paid \$198,000 to the Company and exercised another 2,000,000 options at \$0.132, paying \$264,000 to the Company.

⁽³⁾On 7 October 2024, option holders exercised 4,500,000 million options at 0.089 cents using cashless exercise mechanisms where the result was the issuance of 3,422,643 million ordinary shares of the Company.

	Number 31 December 2024	Number 30 June 2024
Issued Performance Rights		
Unlisted Performance Rights	115,666,666	57,000,000
Movements in options on issue		
Balance at beginning of the period	57,000,000	7,333,335
Issued during the period for remuneration ⁽¹⁾	59,000,000	56,000,000
Lapsed during the period	(333,334)	(6,333,335)
Exercised during the period	-	-
Balance at end of the period	115,666,666	57,000,000

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS (CONTINUED)

31 December 2024 notes:

⁽¹⁾During the period, the Company formally issued 23,000,000 performance rights that were deemed to be granted for accounting purposes during the 30 June 2024 period. Consequently, these were valued and disclosed as part of granted share-based payment arrangements as at 30 June 2024.

During the 31 December 2024 period, the Company issued 36,000,000 performance rights to key management personnel as described under *Options and Performance Rights issued during the 31 December 2024 period* below.

Total expenses arising from share-based payment transactions recognised during the period were as follows:

	31 December 2024	31 December 2023
Share based payments expense	\$	\$
Performance rights and options - current period grants ⁽¹⁾	5,156,019	974,899
Performance rights and options - prior period grants ⁽¹⁾	5,378,982	518,321
Shares issued to consultants for services	58,333	-
Total share-based payments expense	10,593,334	1,493,220

⁽¹⁾ The Group recognises its share-based payments evenly from the grant date to the expected vesting date and, therefore, the expense recorded is from a combination of awards issued in the current period and prior period(s).

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS (CONTINUED)*Options and Performance Rights granted during the 31 December 2024 period*

Employee Performance Rights were granted with the following hurdles, assumptions and details whereby the Rights have been valued at the Company's share price on the grant date:

Type	Performance Rights
Grant date	4 November 2024
Exercise price	\$0.000
Grant date share price	\$0.320
Fair value at grant date	\$0.320
Expected volatility	N/A
Life	5 years
Dividend yield	N/A
Interest rate	N/A
Tranche	No. of Rights
T1 – the date the company has launched Sofdra with the sales force and telemedicine	4,000,000
T2 – achieving US\$100 million of revenue from the sales of products in a financial year	4,000,000
T3 – achieving US\$150 million of revenue from the sales of products in a financial year	4,000,000

Each of the above tranches were granted equally amongst four *key management personnel* (ie. 1,000,000 Rights per tranche): Matthew Callahan, William Bosche, Danny Sharp and Stewart Washer.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS (CONTINUED)

The following performance rights were issued to *key management personnel* Vincent Ippolito:

Type	Performance Rights
Grant date	4 November 2024
Exercise price	\$0.000
Grant date share price	\$0.320
Fair value at grant date	\$0.320
Expected volatility	N/A
Life	5 years
Dividend yield	N/A
Interest rate	N/A
Tranche	No. of Rights
T1 – The date the Company has: - successfully established a distribution network which is effectively providing reimbursed prescriptions to patients; and - executed its first payer contract with a leading US payer for coverage of Sofdra™.	4,000,000
T2 – The date that the Company: -has successfully deployed its digital telehealth platform for the diagnosis of patients with hyperhidrosis; and -is generating revenue from prescriptions as a direct result from utilization of the telehealth platform.	4,000,000
T3 - The date the Company has acquired an FDA approved product or products in the dermatology space which is accretive to annual revenue.	2,000,000
T4 - The date the Company has acquired a late-stage development or commercial ready product in the dermatology space with a market potential of US\$200 million in aggregate sales or greater.	2,000,000
T5 - Achieving US\$100 million of revenue from the sales of products in a financial year.	4,000,000
T6 - Achieving US\$150 million of revenue from the sales of products in a financial year.	4,000,000
T7 - Achieving US\$250 million of revenue from the sale of products in a financial year.	4,000,000

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS (CONTINUED)

The following performance rights were granted to *key management personnel* Chris Lesovitz:

Type	Performance Rights
Grant date	18 December 2024
Number of instruments granted	3,000,000
Exercise price	\$0.000
Grant date share price	\$0.385
Fair value at grant date	\$0.385
Expected volatility	N/A
Life	5 years
Dividend yield	N/A
Interest rate	N/A
Tranche	No. of Rights
T1 – within 1 year of the date of issuance	750,000
T2 – within 2 years of the date of issuance	750,000
T3 – within 3 years of the date of issuance	750,000
T4 – within 4 years of the date of issuance	750,000

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 6: SHARE BASED PAYMENTS (CONTINUED)

The following options and performance rights were granted to employees and consultants who do not represent *key management personnel*:

Type	Performance Rights	Options
Grant dates	Between 23 September 2024 and 18 December 2024	Between 15 July 2024 and 19 December 2024
Number of instruments granted	9,000,000	28,250,000
Exercise price	\$0.000	\$0.34
Grant date share price	\$0.39	\$0.39
Fair value at grant date	\$0.39	\$0.259
Expected volatility	N/A	75%
Life	5 years	5 years
Dividend yield	N/A	-
Interest rate	N/A	4.0%
Tranche	No. of Rights	No. of Options
T1—within 1 year of the date of issuance	2,250,000	7,062,500
T2—within 2 years of the date of issuance	2,250,000	7,062,500
T3—within 3 years of the date of issuance	2,250,000	7,062,500
T4—within 4 years of the date of issuance	2,250,000	7,062,500

All Performance Rights and Options have been recognised as share-based payments expense in the period based on the total fair value amortised evenly from the grant date over the expected vesting period based on estimated achievement dates for each of the hurdles.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 7: RESERVES

	31 December 2024	30 June 2024
	\$	\$
Share based payments reserve		
Balance at beginning of period	10,702,140	6,041,423
Share based payment expense	10,535,001	4,393,092
Exercise of options by employee under the ESIP	-	(79,354)
Issue of options (cost of raising capital)	-	346,981
Balance at end of period	21,237,141	10,702,140
Foreign currency translation reserve		
Balance at beginning of period	501,719	341,878
Effect for foreign currency translation during the	3,588,238	159,841
Balance at end of period	4,089,957	501,719

Share Based Payments Reserve

The share-based payments include the following:

- Items recognised as expenses on valuation of share options and performance rights issued as remuneration to employees; and
- Options issued to non-related parties in exchange for services.

Foreign Currency Translation Reserve

The foreign currency translation reserve includes the following:

- Effect of foreign currency translation of foreign subsidiary at period end.

BOTANIX PHARMACEUTICALS LIMITED

ACN: 009 109 755

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 8: SEGMENT REPORTING

For management purposes, the Group is organised into operating segments geographically. The chief operating decision makers of the Group are the Directors. At 31 December 2024, all revenues and material assets are considered to be derived and held in two geographical areas being Australia and United States as set out below:

	Australia	United States	Total
	31 December	31 December	
	2024	2024	2024
	\$	\$	\$
Revenue from continuing operations	-	345,673	345,673
Other income	1,214,235	-	1,214,235
Expenditure on continuing operations	12,086,026	20,362,001	32,448,027
Current Assets	46,907,942	20,882,746	67,790,688
Non-Current Assets	974,953	30,682,126	31,657,079
Total Assets	47,882,895	51,564,872	99,447,767
Current Liabilities	653,477	5,721,880	6,375,357
Non-Current Liabilities	-	584,408	584,408
Total Liabilities	653,477	6,306,288	6,959,765
Net Assets	47,229,418	45,258,584	92,488,002

	Australia	United States	Total
	31 December	31 December	
	2023	2023	2023
	\$	\$	\$
Revenue from continuing operations	-	377,930	377,930
Other income	41,559	-	41,559
Expenditure on continuing operations	3,130,946	2,755,707	5,886,653

BOTANIX PHARMACEUTICALS LIMITED**ACN: 009 109 755****NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

For the six months ended 31 December 2024

NOTE 8: SEGMENT REPORTING (CONTINUED)

	Australia	United States	Total
	30 June 2024	30 June 2024	2024
	\$	\$	\$
Current Assets	78,686,504	4,214,803	82,901,307
Non-Current Assets	1,006,573	28,556,747	29,563,320
Total Assets	79,693,077	32,771,550	112,464,626
Current Liabilities	375,373	3,356,704	3,732,077
Non-Current Liabilities	-	-	-
Total Liabilities	375,373	3,356,704	3,732,077
Net Assets	79,317,704	29,414,846	108,732,549

NOTE 9: RELATED PARTY TRANSACTIONS

On 5 August 2024, Chris Lesovitz was appointed full time Chief Financial Officer of its U.S. subsidiary companies and U.S. operations. In this role, Mr. Lesovitz earns an annual salary of \$288,000 USD per annum and is eligible for a bonus equivalent to 40% of his annual salary. During the half-year period, Mr. Lesovitz was granted 3,000,000 Performance Rights as disclosed in note 6 above.

As disclosed in note 6, the Company granted an additional 36,000,000 performance rights to key management personnel.

There were no other new related party transactions during the period and since 30 June 2024, nor any related party transactions that were outside the normal course of business.

NOTE 10: CONTINGENT ASSETS & LIABILITIES

There have been no changes to contingent assets and liabilities since 30 June 2024 and therefore no additional disclosure or changes to disclosure from that financial report.

NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

NOTE 11: EVENTS OCCURRING AFTER THE REPORTING PERIOD

On 9 January 2025, the Company issued 12,000,000 performance rights and 31,250,000 options to employees and staff. These instruments were deemed to be granted, for accounting purposes, prior to 31 December 2024 period and therefore accounted for within the 31 December 2024 period or, in the case of 3,000,000 of the options, during the 30 June 2024 period. Refer to Note 6 for details to the 40,250,000 of securities granted during the 31 December 2024 period.

There are no other matters or circumstances which have arisen since the end of the period which significantly affects or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in subsequent financial periods.

DIRECTORS' DECLARATION

In the opinion of the Directors of Botanix Pharmaceuticals Limited:

1. The attached financial statements and notes thereto are in accordance with the Corporations Act 2001 including:
 - a) complying with Accounting Standards AASB 134: 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
 - b) giving a true and fair view of the Group's financial position as of 31 December 2024 and of its performance for the half year then ended.
2. There are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with a resolution of the Board of Directors made pursuant to s.303 (5) of the Corporations Act 2001.

On behalf of the board



Vince Ippolito
Executive Chairman
25 February 2025

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Botanix Pharmaceuticals Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Botanix Pharmaceuticals Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- i. Giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the half-year ended on that date; and
- ii. Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Material uncertainty relating to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is true and fair and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

The image shows a handwritten signature in black ink. The signature appears to be 'Dean Just' written in a cursive, stylized script. Above the signature, the letters 'BDO' are handwritten in a simple, blocky font.

Dean Just

Director

Perth, 25 February 2025